目的 考察羧甲司坦口服溶液联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床效果。方法 选取航空总医院2017年5月—2018年5月收治的支气管哮喘患者133例，随机分成对照组（66例）和治疗组（67例）。对照组患者吸入沙美特罗替卡松粉吸入剂，1泡/次，2次/d；治疗组患者在对照组用药基础上口服羧甲司坦口服溶液，10 mL/次，3次/d。两组患者均连续治疗15 d。观察两组患者临床疗效，同时比较治疗前后两组患者ACT和SF-36评分及血清γ-干扰素（IFN-γ）、白介素-4（IL-4）和白细胞三烯B4（LTB4）水平。结果 治疗后，对照组临床有效率为80.30%，显著低于治疗组的95.52%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者ACT评分和SF-36评分均显著升高（P<0.05），且治疗组ACT和SF-36评分明显高于对照组（P<0.05）。治疗后，两组患者血清IFN-γ水平显著升高（P<0.05），血清IL-4、LTB4水平显著降低（P<0.05），且治疗组血清IFN-γ、IL-4、LTB4水平明显好于对照组（P<0.05）。结论 羧甲司坦口服溶液联合沙美特罗替卡松粉吸入剂治疗支气管哮喘疗效显著，且能够明显降低机体炎症水平，可作为支气管哮喘的临床一线治疗方案。

Objective To investigate the clinical efficacy of carbostatin combined with salmeterol in treatment of bronchial asthma. Methods Patients (133 cases) with bronchial asthma in Aviation General Hospital from May 2017 to May 2018 were randomly divided into control (66 cases) and treatment (67 cases) groups. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 inhalation/time, twice daily. Patients in the treatment group were po administered with Carbocysteine Oral Solution on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the ACT and SF-36 scores, IFN-γ, IL-4 and LTB4 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.30%, which was significantly lower than 95.52% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the ACT and SF-36 scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum IFN-γ levels in two groups were significantly increased (P<0.05), but IL-4 and LTB4 levels were significantly decreased (P<0.05), and the IFN-γ, IL-4 and LTB4 levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion carbostatin combined with salmeterol in treatment of bronchial asthma has significant clinical efficacy, and can significantly reduce the inflammation level, which can be used as a clinical first-line treatment for bronchial asthma.